Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041872 | 0.83 | NOTUM (0.39) | NOTUMIDO1 | |
| SCHEMBL18238741 | 0.80 | ACHE (0.40) | NOTUM | |
| SCHEMBL25763075 | 0.77 | NOTUM (0.45) | NOTUMPDE3BPDE3A | |
| SCHEMBL18234142 | 0.77 | MPL (0.41) | PDE3BPDE3A | |
| SCHEMBL18238072 | 0.77 | ACHE (0.38) | — | |
| SCHEMBL1042014 | 0.75 | NOTUM (0.47) | NOTUMIDO1PDE3BPDE3A | |
| SCHEMBL12226216 | 0.75 | AHR (0.43) | NOTUMIDO1 | |
| SCHEMBL31250605 | 0.75 | AHR (0.43) | NOTUMIDO1 | |
| SCHEMBL1076587 | 0.75 | ACHE (0.34) | — | |
| SCHEMBL1042022 | 0.74 | RAPGEF4 (0.38) | IDO1RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| EP-2272852-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | Sumitomo Chemical Company, Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-06-04 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1683802-A1 | TRANSITION METAL COMPLEX LIGAND AND OLEFIN POLYMERIZATION CATALYST CONTAINING TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | NOTUM 4325/4885IDO1 2706/4885HTR3E 4106/4885 |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | NOTUM 4325/4885IDO1 2706/4885HTR3E 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.